MDT

81.74

-1.59%ā†“

VEEV

209.29

-2.32%ā†“

A

98.9

-4.01%ā†“

HQY

76.28

-4.98%ā†“

PDCO

31.05

+0.49%ā†‘

MDT

81.74

-1.59%ā†“

VEEV

209.29

-2.32%ā†“

A

98.9

-4.01%ā†“

HQY

76.28

-4.98%ā†“

PDCO

31.05

+0.49%ā†‘

MDT

81.74

-1.59%ā†“

VEEV

209.29

-2.32%ā†“

A

98.9

-4.01%ā†“

HQY

76.28

-4.98%ā†“

PDCO

31.05

+0.49%ā†‘

MDT

81.74

-1.59%ā†“

VEEV

209.29

-2.32%ā†“

A

98.9

-4.01%ā†“

HQY

76.28

-4.98%ā†“

PDCO

31.05

+0.49%ā†‘

MDT

81.74

-1.59%ā†“

VEEV

209.29

-2.32%ā†“

A

98.9

-4.01%ā†“

HQY

76.28

-4.98%ā†“

PDCO

31.05

+0.49%ā†‘

Search

Lyell Immunopharma Inc

Closed

0.4 -6.98

Overview

Share price change

24h

Current

Min

0.4

Max

0.47

Key metrics

By Trading Economics

Income

-147M

-192M

Sales

-23K

11K

EPS

-0.172

Profit margin

-1,744,863.636

Employees

300

EBITDA

-12M

-58M

Recommendations

By TipRanks

Recommendations

Sell

12 Months Forecast

+117.39% upside

Dividends

By Dow Jones

Next Earnings

5 May 2025

Market Stats

By TradingEconomics

Market Cap

-79M

137M

Previous open

7.38

Previous close

0.4

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Lyell Immunopharma Inc Chart

Past performance is not a reliable indicator of future results.

Related News

8 Apr 2025, 22:42 UTC

Major Market Movers

Peabody Energy Shares Climb on Trump Executive Orders Boosting Coal Industry

8 Apr 2025, 22:35 UTC

Earnings
Major Market Movers

Cal-Maine Foods Shares Fall As Justice Dept Probes Egg Prices

8 Apr 2025, 21:30 UTC

Earnings

Cal-Maine Foods Cooperating With Justice Dept Probe Into Egg Price Increases -- Update

8 Apr 2025, 21:21 UTC

Earnings

Cal-Maine Foods Cooperating With Justice Dept Probe into Egg Price Increases

9 Apr 2025, 00:00 UTC

Top News

Trump's Tariffs Put Fed Chair Powell in a 'No-Win Situation' -- WSJ

8 Apr 2025, 23:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 Apr 2025, 23:45 UTC

Market Talk

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

8 Apr 2025, 23:43 UTC

Market Talk

Lithium Oversupply Weighs on Price Outlook -- Market Talk

8 Apr 2025, 23:43 UTC

Acquisitions, Mergers, Takeovers

Woolworths' Rivals Have Other Options to Source Ready Meals, ACCC Says

8 Apr 2025, 23:42 UTC

Market Talk

Gold Falls on Possible Unwinding of Long Positions to Raise Cash -- Market Talk

8 Apr 2025, 23:42 UTC

Acquisitions, Mergers, Takeovers

Beak & Johnston Makes Ready Meals, Pastries for Wholesale, Retail

8 Apr 2025, 23:41 UTC

Acquisitions, Mergers, Takeovers

Woolworths' Acquisition Unlikely to Have Substantial Anti-Competitive Effect, ACCC Says

8 Apr 2025, 23:40 UTC

Acquisitions, Mergers, Takeovers

Australian Competition and Consumer Commission: Will Not Oppose Transaction

8 Apr 2025, 23:39 UTC

Acquisitions, Mergers, Takeovers

Australian Competition Regulator to Allow Woolworths' Acquisition of Beak & Johnston

8 Apr 2025, 23:21 UTC

Acquisitions, Mergers, Takeovers

U.S. Steel: $75 per Shr That the Ancora 'Plan' Proposes Is Really an Unrealistic, Distant Future Value Pipedream Rooted Firmly in Fiction >X

8 Apr 2025, 23:21 UTC

Acquisitions, Mergers, Takeovers

U.S. Steel: Stockholders Should Be Very Skeptical of Ancora's 'Plan' or That Their Nominees Could or Would Vigorously Fight for the Nippon Steel Deal >X

8 Apr 2025, 21:26 UTC

Top News

When Coffee Mate Made a 'White Lotus' PiƱa Colada Creamer, It Had No Idea How the Season Would End -- WSJ

8 Apr 2025, 21:26 UTC

Earnings

Pfizer Stock's Fall to '97 Level Lifts Yield Near 8%. Dividend Looks Safe. -- Barrons.com

8 Apr 2025, 21:18 UTC

Acquisitions, Mergers, Takeovers

Peabody Energy: Remains in Conversation With Anglo Amer to Better Understand Impacts of Event, Preserving All Rights and Protections Under Purchase Agreements >BTU

8 Apr 2025, 21:18 UTC

Acquisitions, Mergers, Takeovers

Peabody Energy: Following Ignition Event Last Week at Anglo Amer's Moranbah North Mine, Reviewing Options Related to Acquisition of Steelmaking Coal Assets From Anglo Amer >BTU

8 Apr 2025, 21:06 UTC

Top News

Stocks Are in Turmoil, but Treasury Yields Are Stubbornly High -- Update

8 Apr 2025, 20:50 UTC

Top News

Harley-Davidson Seeks New CEO, Facing Sales Slump and Tariffs -- 3rd Update

8 Apr 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8 Apr 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8 Apr 2025, 20:40 UTC

Earnings

BYD Stock Soars. It's Catching Up to Tesla in Yet Another Way. -- Barrons.com

8 Apr 2025, 20:28 UTC

Earnings

Sandstorm Gold: Will Release 1Q Results on May 6 After Markets Close >SSL.T

8 Apr 2025, 20:28 UTC

Earnings

Sandstorm Gold: During Three Mos Ended March 31, Realized Record Preliminary Revenue of $50.1M (20,316 Attributable Gold Equivalent Ounces and $42.8M in Rev for the Comparable Period in 2024) >SSL.T

8 Apr 2025, 20:28 UTC

Earnings

Sandstorm Gold: Record Preliminary Total Sales, Royalties, Income From Other Interests of $54.1M for Three Mos Ended March 31 ($42.8M in Total Sales, Royalties, Income From Other Interests for Comparable Period in 2024) >SSL.T

8 Apr 2025, 20:28 UTC

Earnings

Sandstorm Gold: During Three Mos Ended March 31, Sold Approximately 18,500 Attributable Gold Equivalent Ounces >SSL.T

8 Apr 2025, 20:14 UTC

Top News

U.S. Stocks Retreat as Optimism Over Trade Talks Fades -- WSJ

Peer Comparison

Price change

Lyell Immunopharma Inc Forecast

Price Target

By TipRanks

117.39% upside

12 Months Forecast

Average 1 USD  117.39%

High 1 USD

Low 1 USD

Based on 2 Wall Street analysts offering 12 month price targets forLyell Immunopharma Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Sell

2 ratings

0

Buy

1

Hold

1

Sell

Technical Score

By Trading Central

0.445 / 0.482Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

No Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Lyell Immunopharma Inc

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.